Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
EBOS Group buys, warehouses and delivers medicines, medical supplies and animal care products to pharmacies, hospitals and clinics across Australia and New Zealand.
EBOS Group is the quiet plumbing behind a huge share of Australasian healthcare. When you walk into a pharmacy in Australia or New Zealand, a large portion of what sits on the shelves — medicines, vitamins, bandages, cosmetics, even the lollies near the counter — likely passed through one of its warehouses. When a hospital needs a surgical kit or an IV drip, EBOS is one of the biggest suppliers that gets it there. In short, it is a giant middleman: it buys products from thousands of manufacturers, stores them, and ships them out to pharmacies, hospitals and clinics that would otherwise have to deal with every supplier themselves.
The business runs in two main parts. One is healthcare distribution, which includes pharmaceutical wholesaling to community pharmacies and hospitals, plus its own brands of over-the-counter products and medical devices sold under names like Chemist's Own and Medifab. The other is animal care, where EBOS is a major supplier of veterinary medicines, pet food and farm supplies, mostly in New Zealand, through businesses such as its animal health arm. There is also a smaller contract logistics piece — it stores and ships products for other companies that don't want to run their own warehouses. The magic of the model is scale and reliability. Pharmacies order small amounts frequently — they can't afford to hold piles of stock — so the distributor that can get them almost anything by the next morning wins. EBOS has spent decades building that network and buying up rivals to widen it, including big deals like the acquisition of Symbion in 2013, which roughly tripled its size overnight. That deal turned EBOS from a New Zealand-focused company into a genuine trans-Tasman heavyweight. The flip side is that wholesale margins are thin: it makes a little on each item but moves enormous volumes, so the business lives or dies on efficiency.
The main vulnerability is that this is a regulated, low-margin game where customers have real bargaining power. Big pharmacy chains and hospital groups negotiate hard, and governments keep an eye on medicine prices and distribution rules. But EBOS has generally turned that squeeze into steady growth, and it uses its cash to pay dividends, make bolt-on acquisitions and keep expanding its warehouse and logistics footprint. It is not a glamorous business — no blockbuster drugs, no flashy technology — but it is the kind of dependable toll booth that healthcare systems quietly depend on every single day.
Saved answer · last researched 15 Nov 2026